Advertisement

Clinical, Imaging, and CSF Cytological Presentation of Leptomeningeal Metastases from Solid Non-CNS Primary Tumors

  • Emilie Le RhunEmail author
  • Michael Weller
Chapter

Abstract

The diagnosis of leptomeningeal metastasis (LM) is based on a clinical assessment, cerebrospinal magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) cytological analysis. The diagnosis can be challenging since LM can cause a variety of neurological symptoms and signs and since there are multiple differential diagnoses to consider as a cause of neurological problems in patients that are often in advanced stages of the disease. The EANO ESMO guideline defines the diagnosis of LM as confirmed if malignant cells are found in the CSF or by biopsy. The diagnosis is probable in the case of typical clinical symptoms and signs and typical neuroimaging findings in patients with metastatic cancer. Repeated assessments may be necessary if the diagnosis of LM remains doubtful. The diagnostic role of novel molecular liquid biopsy markers is under evaluation.

Keywords

Carcinomatous Cerebrospinal Cytometry EpCAM Flow Fluid Genomic Meningitis Methylation MRI 

References

  1. 1.
    Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv Neurol. 1978;19:579–92.Google Scholar
  2. 2.
    Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R, et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol Off J Eur Soc Med Oncol. 2017;28(suppl_4):iv84–99.CrossRefGoogle Scholar
  3. 3.
    Roelz R, Reinacher P, Jabbarli R, Kraeutle R, Hippchen B, Egger K, et al. Surgical ventricular entry is a key risk factor for leptomeningeal metastasis of high grade gliomas. Sci Rep. 2015;5:17758.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Ahn JH, Lee SH, Kim S, Joo J, Yoo H, Lee SH, et al. Risk for leptomeningeal seeding after resection for brain metastases: implication of tumor location with mode of resection. J Neurosurg. 2012;116(5):984–93.CrossRefGoogle Scholar
  5. 5.
    Elliott JP, Keles GE, Waite M, Temkin N, Berger MS. Ventricular entry during resection of malignant gliomas: effect on intracranial cerebrospinal fluid tumor dissemination. J Neurosurg. 1994;80(5):834–9.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    van der Ree TC, Dippel DW, Avezaat CJ, Sillevis Smitt PA, Vecht CJ, van den Bent MJ. Leptomeningeal metastasis after surgical resection of brain metastases. J Neurol Neurosurg Psychiatry. 1999;66(2):225–7.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Norris LK, Grossman SA, Olivi A. Neoplastic meningitis following surgical resection of isolated cerebellar metastasis: a potentially preventable complication. J Neurooncol. 1997;32(3):215–23.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Suki D, Hatiboglu MA, Patel AJ, Weinberg JS, Groves MD, Mahajan A, et al. Comparative risk of leptomeningeal dissemination of cancer after surgery or stereotactic radiosurgery for a single supratentorial solid tumor metastasis. Neurosurgery. 2009;64(4):664–74.. discussion 674–676PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Abouharb S, Ensor J, Loghin ME, Katz R, Moulder SL, Esteva FJ, et al. Leptomeningeal disease and breast cancer: the importance of tumor subtype. Breast Cancer Res Treat. 2014;146(3):477–86.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Li Y-S, Jiang B-Y, Yang J-J, Tu H-Y, Zhou Q, Guo W-B, et al. Leptomeningeal metastases in patients with NSCLC with EGFR mutations. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2016;11(11):1962–9.Google Scholar
  11. 11.
    Chamberlain M, Junck L, Brandsma D, Soffietti R, Rudà R, Raizer J, et al. Leptomeningeal metastases: a RANO proposal for response criteria. Neuro-Oncol. 2017;19:484–92.PubMedCrossRefGoogle Scholar
  12. 12.
    Chamberlain M, Soffietti R, Raizer J, Rudà R, Brandsma D, Boogerd W, et al. Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro-Oncol. 2014;16(9):1176–85.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Singh SK, Leeds NE, Ginsberg LE. MR imaging of leptomeningeal metastases: comparison of three sequences. AJNR Am J Neuroradiol. 2002;23(5):817–21.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Mahendru G, Chong V. Meninges in cancer imaging. Cancer Imaging Off Publ Int Cancer Imaging Soc. 2009;9:S14–21.Google Scholar
  15. 15.
    de Azevedo CRAS, Cruz MRS, Chinen LTD, Peres SV, Peterlevitz MA, de Azevedo Pereira AE, et al. Meningeal carcinomatosis in breast cancer: prognostic factors and outcome. J Neurooncol. 2011;104(2):565–72.PubMedCrossRefGoogle Scholar
  16. 16.
    Gauthier H, Guilhaume MN, Bidard FC, Pierga JY, Girre V, Cottu PH, et al. Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol Off J Eur Soc Med Oncol. 2010;21(11):2183–7.CrossRefGoogle Scholar
  17. 17.
    Meattini I, Livi L, Saieva C, Franceschini D, Marrazzo L, Greto D, et al. Prognostic factors and clinical features in patients with leptominengeal metastases from breast cancer: a single center experience. J Chemother Florence Italy. 2012;24(5):279–84.CrossRefGoogle Scholar
  18. 18.
    Lara-Medina F, Crismatt A, Villarreal-Garza C, Alvarado-Miranda A, Flores-Hernández L, González-Pinedo M, et al. Clinical features and prognostic factors in patients with carcinomatous meningitis secondary to breast cancer. Breast J. 2012;18(3):233–41.PubMedCrossRefGoogle Scholar
  19. 19.
    Le Rhun E, Taillibert S, Zairi F, Kotecki N, Devos P, Mailliez A, et al. A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer. J Neurooncol. 2013;113(1):83–92.PubMedCrossRefGoogle Scholar
  20. 20.
    Torrejón D, Oliveira M, Cortes J, Sanchez-Olle G, Gómez P, Bellet M, et al. Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis. Breast Edinb Scotl. 2013;22(1):19–23.CrossRefGoogle Scholar
  21. 21.
    Yust-Katz S, Garciarena P, Liu D, Yuan Y, Ibrahim N, Yerushalmi R, et al. Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis. J Neurooncol. 2013;114(2):229–35.PubMedCrossRefGoogle Scholar
  22. 22.
    Morikawa A, Jordan L, Rozner R, Patil S, Boire A, Pentsova E, et al. Characteristics and outcomes of patients with breast cancer with leptomeningeal metastasis. Clin Breast Cancer. 2017;17(1):23–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Niwińska A, Pogoda K, Michalski W, Kunkiel M, Jagiełło-Gruszfeld A. Determinants of prolonged survival for breast cancer patient groups with leptomeningeal metastasis (LM). J Neurooncol. 2018;138(1):191–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Umemura S, Tsubouchi K, Yoshioka H, Hotta K, Takigawa N, Fujiwara K, et al. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. Lung Cancer Amst Neth. 2012;77(1):134–9.CrossRefGoogle Scholar
  25. 25.
    Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2012;7(2):382–5.Google Scholar
  26. 26.
    Park JH, Kim YJ, Lee J-O, Lee K-W, Kim JH, Bang S-M, et al. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer Amst Neth. 2012;76(3):387–92.CrossRefGoogle Scholar
  27. 27.
    Gwak H-S, Joo J, Kim S, Yoo H, Shin SH, Han J-Y, et al. Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2013;8(5):599–605.Google Scholar
  28. 28.
    Lee SJ, Lee J-I, Nam D-H, Ahn YC, Han JH, Sun J-M, et al. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2013;8(2):185–91.Google Scholar
  29. 29.
    Riess JW, Nagpal S, Iv M, Zeineh M, Gubens MA, Ramchandran K, et al. Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. Clin Lung Cancer. 2014;15(3):202–6.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Kuiper JL, Hendriks LE, van der Wekken AJ, de Langen AJ, Bahce I, Thunnissen E, et al. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: a retrospective cohort analysis. Lung Cancer Amst Neth. 2015;89(3):255–61.CrossRefGoogle Scholar
  31. 31.
    Harstad L, Hess KR, Groves MD. Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neuro-Oncol. 2008;10(6):1010–8.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Geukes Foppen MH, Brandsma D, Blank CU, van Thienen JV, Haanen JB, Boogerd W. Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma. Ann Oncol Off J Eur Soc Med Oncol. 2016;27(6):1138–42.CrossRefGoogle Scholar
  33. 33.
    Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL, Bernatchez C, Diab A, et al. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open. 2018;3(1):e000283.. [Internet] [cited 2018 Dec 30]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786950/PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Kwon J, Chie EK, Kim K, Kim HJ, Wu H-G, Kim IH, et al. Impact of multimodality approach for patients with leptomeningeal metastases from solid tumors. J Korean Med Sci. 2014;29(8):1094–101.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Rudnicka H, Niwińska A, Murawska M. Breast cancer leptomeningeal metastasis—the role of multimodality treatment. J Neurooncol. 2007;84(1):57–62.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Glantz MJ, Cole BF, Glantz LK, Cobb J, Mills P, Lekos A, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer. 1998;82(4):733–9.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Rogers LR, Duchesneau PM, Nunez C, Fishleder AJ, Weick JK, Bauer LJ, et al. Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis. Neurology. 1992;42(6):1239–41.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Dux R, Kindler-Röhrborn A, Annas M, Faustmann P, Lennartz K, Zimmermann CW. A standardized protocol for flow cytometric analysis of cells isolated from cerebrospinal fluid. J Neurol Sci. 1994;121(1):74–8.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Quijano S, López A, Manuel Sancho J, Panizo C, Debén G, Castilla C, et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin’s lymphoma: improved sensitivity of flow cytometry. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(9):1462–9.CrossRefGoogle Scholar
  40. 40.
    CellSearch circulating tumor cell kit premarket notification—expanded indications for use—colorectal. Available at https://www.accessdata.fda.gov/cdrh_docs/pdf7/k071729.pdf
  41. 41.
    Nayak L, Fleisher M, Gonzalez-Espinoza R, Lin O, Panageas K, Reiner A, et al. Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors. Neurology. 2013;80(17):1598–605.. discussion 1603PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Lee JS, Melisko ME, Magbanua MJM, Kablanian AT, Scott JH, Rugo HS, et al. Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. Breast Cancer Res Treat. 2015;154(2):339–49.PubMedCrossRefGoogle Scholar
  43. 43.
    Tu Q, Wu X, Le Rhun E, Blonski M, Wittwer B, Taillandier L, et al. CellSearch technology applied to the detection and quantification of tumor cells in CSF of patients with lung cancer leptomeningeal metastasis. Lung Cancer Amst Neth. 2015;90(2):352–7.CrossRefGoogle Scholar
  44. 44.
    Patel AS, Allen JE, Dicker DT, Peters KL, Sheehan JM, Glantz MJ, et al. Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget. 2011;2(10):752–60.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Le Rhun E, Massin F, Tu Q, Bonneterre J, Bittencourt MDC, Faure GC. Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis. BMC Clin Pathol. 2012;12:21.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Le Rhun E, Tu Q, De Carvalho Bittencourt M, Farre I, Mortier L, Cai H, et al. Detection and quantification of CSF malignant cells by the CellSearch technology in patients with melanoma leptomeningeal metastasis. Med Oncol Northwood Lond Engl. 2013;30(2):538.CrossRefGoogle Scholar
  47. 47.
    Campoli MR, Chang C-C, Kageshita T, Wang X, McCarthy JB, Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol. 2004;24(4):267–96.PubMedCrossRefGoogle Scholar
  48. 48.
    van Bussel MTJ, Pluim D, Bol M, Beijnen JH, Schellens JHM, Brandsma D. EpCAM-based assays for epithelial tumor cell detection in cerebrospinal fluid. J Neurooncol. 2018;137(1):1–10.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Magbanua MJM, Roy R, Sosa EV, Hauranieh L, Kablanian A, Eisenbud LE, et al. Genome-wide copy number analysis of cerebrospinal fluid tumor cells and their corresponding archival primary tumors. Genomics Data. 2014;2:60–2.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Sasaki S, Yoshioka Y, Ko R, Katsura Y, Namba Y, Shukuya T, et al. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure. Respir Investig. 2016;54(1):14–9.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Li Y, Pan W, Connolly ID, Reddy S, Nagpal S, Quake S, et al. Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases. J Neurooncol. 2016;128(1):93–100.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Shingyoji M, Kageyama H, Sakaida T, Nakajima T, Matsui Y, Itakura M, et al. Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2011;6(7):1215–20.Google Scholar
  53. 53.
    Yang H, Cai L, Zhang Y, Tan H, Deng Q, Zhao M, et al. Sensitive detection of EGFR mutations in cerebrospinal fluid from lung adenocarcinoma patients with brain metastases. J Mol Diagn JMD. 2014;16(5):558–63.PubMedCrossRefGoogle Scholar
  54. 54.
    Seoane J, De Mattos-Arruda L, Le Rhun E, Bardelli A, Weller M. Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. Ann Oncol Off J Eur Soc Med Oncol. 2018;30:211–8.CrossRefGoogle Scholar
  55. 55.
    De Mattos-Arruda L, Mayor R, Ng CKY, Weigelt B, Martínez-Ricarte F, Torrejon D, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6:8839.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Yang JC-H, Kim D-W, Kim S-W, Cho BC, Lee J-S, Ye X, et al. Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): updated results from BLOOM, a phase I study. J Clin Oncol. 2016;34(15_suppl):9002.CrossRefGoogle Scholar
  57. 57.
    Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555(7697):469–74.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.University Hospital Lille, U-1192LilleFrance
  2. 2.Inserm, U-1192LilleFrance
  3. 3.Breast Cancer DepartmentOscar Lambret CenterLilleFrance
  4. 4.Neurology, Breast Cancer DepartmentOscar Lambret CenterLille CedexFrance
  5. 5.Department of Neurology & Brain Tumor CenterUniversity Hospital and University of ZurichZurichSwitzerland

Personalised recommendations